Disease Areas
News and analysis on disease research and diagnostics.
FDA Approves Blue Earth Diagnostics' PSMA-Targeted Radiohybrid PET Imaging Agent
The agency approved Posluma for detecting PSMA-positive lesions in prostate cancer patients whose tumors are suspected to have metastasized or recurred.
Bioinformatics Tool for Tracking Tumor-Immune Interactions Could Be Useful for Guiding Therapy
Premium
A map for discovering immune checkpoints and tumor process interactions is showing potential in identifying new drug targets and personalizing immunotherapy.
Real-World Study Examines Genomic Profiling Challenges for Patients With Cancers of Unknown Primary
Premium
The researchers found that more than half of patients with CUP did not have sufficient tissue to undergo genomic profiling.
In Brief This Week: Clarity Pharmaceuticals, Regenxbio, Rocket Pharmaceuticals, Eisai, AstraZeneca
News items for the week of May 22, 2023.
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.